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Concurrent HPV-related oropharyngeal carcinoma in four couples 
 
Abstract 
Objectives 
Typically, HPV-related cancers are sexually transmitted, however, the natural history 
of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) is unclear. HPV16 
transmission has been reported previously between five couples with OPSCC. We 
report the clinico-pathological features of a further four couples with HPV-related 
OPSCC and compare them with the published cases. 
Patients and Methods 
We identified four couples in long-term heterosexual relationships that all had HPV-
related OPSCC. The couples were treated at three UK hospitals and presented 
between 2009-2015. HPV tests included p16 immunohistochemistry, high-risk HPV 
DNA in-situ hybridization and Roche Cobas HPV test. DNA sequencing was used to 
determine the HPV variant. 
Results 
The four couples represented <2% of patients with HPV-related OPSCC at the three 
contributing hospitals (8 of 457 consecutive patients). The couples’ tumours all 
contained HPV16. The mean age was 63 years old (range 52-72 years). The interval 
between the index cancer and the partner’s cancer was 16, 24, 26 and 64 months 
respectively. The majority of patients had Stage I disease (UICC TNM8). Six of eight 
patients are disease free, one patient is alive with disease and there was one death 
from loco-regional recurrence. 
Conclusion 
This report highlights the occurrence of HPV-related OPSCC in heterosexual couples 
and raises the possibility of transmission of HPV16. Despite increasing prevalence of 
HPV-related OPSCC and increased awareness of the disease, there is a paucity of 
couples with the disease, suggesting either under-reporting or that the development 
of OPSCC following HPV transmission between couples is a rare event. 
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Introduction 
It is well known that human papillomavirus (HPV) causes cervical squamous cell 
carcinoma. The natural history of the disease has been well characterized over the 
last 30 years and this knowledge underpins screening programs and vaccination 
strategies for women [1]. More recently, an increase in oropharyngeal squamous cell 
carcinoma (OPSCC) in the USA and Europe has been attributed to oncogenic HPV 
infection [2–4], however, the natural history of the disease is unclear [5]. 
 
There are epidemiological studies showing an association of HPV-related OPSCC 
with sexual behaviour [6–8]. A recent systematic review has also suggested that there 
is a small increased risk for HPV-related cancers amongst spouses/partners of 
patients with HPV-driven cancers [9]. Furthermore, population studies in Sweden 
indicated that women with cervical cancer and their husbands both have a higher 
standard incidence ratio of tonsillar cancer and upper aerodigestive cancers [10,11]. 
These studies provide circumstantial evidence that HPV transmission between 
individuals can result in OPSCC, however, there is no evidence of direct transmission 
and causation per se. 
 
Only five couples with HPV-related OPSCC have been reported to date [12–15]. For 
each set of couples, DNA sequencing of the tumours revealed distinct HPV16 variants 
shared by partners, increasing the likelihood that the virus was acquired by direct 
transmission and was causative. 
 
Interestingly, D’Souza et al (2014) reported that oncogenic HPV could be detected in 
the oral cavities of around 60% of patients with HPV–related OPSCC, but their 
partners had a very low prevalence of oncogenic HPV DNA; around 1.1% [16]. These 
data suggest partners of patients with HPV-related OPSCC have a very low risk of 
oral HPV transmission and consequently a small or negligible risk of developing HPV-
related OPSCC [17]. Here we report the clinico-pathological features of four couples 
with HPV-related OPSCC and compare them with the previously published cases. We 
use the cases to frame a discussion around infectivity, transmission and the natural 
history of HPV-related OPSCC. 
 
Methods 
We identified patients with HPV-related OPSCC that were in long-term heterosexual 
relationships with a partner that also had HPV-related OPSCC from a prospective 
database of patients with HPV-related OPSCC from three UK hospitals (Cancer 
centers at City Hospitals Sunderland, Newcastle upon Tyne Hospitals and North 
Cumbria University Hospital) compiled from January 2009 until December 2017 (9 
years). Written consent was obtained from the patients to use their anonymized clinical 
data for publication. Following patient consent, the clinical features were determined 
by review of the medical notes and the HPV tests were re-examined. p16 was detected 
by immunohistochemistry (CINtec Histology, Roche mtm laboratories AG, Germany) 
and high-risk HPV DNA was detected by in-situ hybridisation (Inform HPV III Family 
16 Probe B, Ventana Medical Systems Inc, USA), using a Benchmark Ultra autostainer 
(Roche Molecular Systems Inc. USA), according to the manufacturer’s instructions. 
 
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue scrolls 
using the Cobas DNA extraction kit (Roche Molecular Systems Inc. USA). Standard 
operating procedures were followed to prevent contamination of samples during 
preparation for downstream analysis. In addition, control samples (known positive and 
negative OPSCC) were prepared alongside test samples to quality assure the results.  
400ng of genomic DNA was analysed using the Cobas HPV test on a Cobas 4800 unit 
(Roche Molecular Systems Inc. USA), according to the manufacturer’s instructions. 
The Cobas HPV test is clinically validated and FDA approved for use in cervical 
screening. 
 
The sequence of HPV was determined by PCR amplification using two sets of primers 
that amplify regions nucleotides 75 to 206 and 274 to 338 within E6 gene as previously 
published [18,19]. Sequencing was performed on purified PCR product (Source 
Bioscience, UK) and sequences were analysed using the reference HPV-16 sequence 
(K02718) [20]. 
 
Results 
The four couples represented <2% of patients with HPV-related OPSCC at the three 
contributing hospitals (8 of 457 consecutive patients, 1.75%). The clinico-pathological 
features of the four couples (8 patients) are summarised in Table 1. Briefly, the mean 
age of the individuals at diagnosis was 63 years old (range 52-72 years). The 
relationships were long-standing (mean duration 36 years; range 24-50 years). The 
index tumour was equally likely to be the male or female in the relationship (2 males, 
2 females). The interval between presentation of the index cancer and the partner 
cancer was 16, 24, 26, and 64 months respectively. The majority of patients were 
never smokers (6 of 8 patients) and where alcohol consumption was known, there 
were equal numbers between those who consumed alcohol and those that did not. 
None of the patients had undergone a tonsillectomy prior to the diagnosis of oro-
pharyngeal cancer. None of the female patients had a history of uterine cervix 
dysplasia or cancer. The majority of patient had Stage I disease (UICC TNM8) and all 
patients were treated with curative intent. Treatment was variable and included 
surgery alone, surgery with adjuvant radiotherapy and chemoradiotherapy, however, 
the majority received chemoradiotherapy (6 of 8 patients). Six of eight patients are 
disease free, one patient is alive with disease and there was one death from loco-
regional recurrence. 
 
All tumours were p16 positive by immunohistochemistry using the validated clinical cut 
off of strong and diffuse nuclear and cytoplasmic expression in >70% of the malignant 
cells [21,22]. The majority of cases (7 of 8 patients) showed evidence of high risk HPV 
DNA by in situ hybridization; one case was negative. The HPV Cobas tests 
demonstrated that all the samples contained amplifiable HPV16 DNA (Table 1). 
 
HPV sequencing results demonstrated that all the couples harboured the European 
A1 lineage of HPV16. Couple 1 harboured a mutation at nucleotide position 350 
changing the nucleotide T to G (indicated as T350G mutation). Interestingly, in Couple 
4, only the female partner had the T350G mutations whereas the corresponding male 
partner had the European A1 variant of HPV-16. 
 
The clinico-pathological features of the previously published cases are presented in 
Table 2. Analysing all the cases (9 couples/18 patients), the mean age of the 
individuals at diagnosis was 62 years old (range 52-75 years old). The relationships 
were long-standing (mean duration 29 years; range 10-50 years). The index tumour 
was equally likely to be the male or female in the relationship (4 males, 4 females, 1 
synchronous). Where smoking status was known, most were never smokers (10 of 16 
patients) and only one was a smoker at diagnosis. Where alcohol consumption was 
known, the majority did not consume alcohol (8 of 14 patients). The majority of patients 
(13 of 18) presented with Stage I disease (UICC/AJCC TNM8). All cancers harboured 
HPV16. Treatment was variable and included surgery alone, surgery with adjuvant 
radiotherapy and chemoradiotherapy, however, the majority received some form of 
chemoradiotherapy (11 of 18 patients). The patients generally had a favorable 
outcome and for those with follow up data, 13 of 14 were survivors; one died of loco-
regional recurrence. 
 
Discussion 
These 18 cases of HPV-related OPSCC in nine longstanding heterosexual 
relationships have features that indicate a high likelihood of transmission of the 
aetiological agent to the partner. All 18 cases harbored HPV-16, which accounts for 
around 90% of HPV-related OPSCC [23]. 
 
Gene sequencing of HPV DNA from the four couples previously reported [13–15] 
revealed that each individual couple had highly phylogenetically similar HPV16 strains 
between the partners, making transmission highly likely in these instances although 
the possibility of a similar source of infection cannot be completely ruled out [13–15]. 
Some sequence variations were reported in all three reports but all had the nucleotide 
T at positions 350. In the four couples from our series however, we found that Couple 
1 and the female of Couple 4 had the G nucleotide in this position. This nucleotide 
change causes an amino acid change of Leucine to Valine at position 83 (L83V). There 
is evidence to suggest that 350G variant is significantly associated with high grade 
cervical lesions and invasive cervical cancer [24]. However, an HPV variant study 
conducted in 2013 found that it was dependent on geographical location [25]. While 
350G E6 was associated with an increased risk of developing cervical cancer in 
Central and South America, this was not the case in Europe or Central Asia. There is 
limited data on T350G mutation in OPSCC. None of the previous case studies 
indicated the presence of this mutation. 
 
It is well known that HPV is a ubiquitous infective agent and around 80% of sexually 
active adults have acquired genital infection at some point during their lifetime, 
however, the majority of infections are cleared [26]. Oral HPV infection has a bimodal 
age distribution, with peak prevalence among individuals aged 55-64 years old [27] 
and the majority of the individuals in this study fitted this demographic. Partners in 
longstanding relationships have already likely shared their infections, which in these 
partners would have been shared for at least a decade and for one couple almost five 
decades, perhaps long enough to facilitate HPV-driven carcinogenesis [17]. 
Furthermore, couples tend to share other environmental risk factors for the 
development of cancer, such as smoking in lung cancer and ultra-violet (UV) radiation 
in skin cancer [10]. However, smoking did not appear to influence the development of 
the cancers documented here, as the majority were never smokers or current non-
smokers. Perhaps factors such as advanced age, co-morbidities and diet, with their 
known effects on immune competence, may have reduced the ability to combat the 
virus with inexorable progression to cancer; however, this is speculative. 
 
Only 1.75% of patients with HPV-related OPSCC were couples in this cohort. Despite 
the obvious lack of infectivity from HPV-related OPSCC as described by D’Souza et 
al (2014) [16], it is possible that the HPV-16 variants in these couples have subtly 
different virulence factors, which makes persistent infection more likely, rendering the 
virus more oncogenic [14]. It is conceivable that virulence factors are encoded by 
acquired virus mutations or epigenetic changes, however, further understanding of the 
natural history of the disease in the oropharynx is required to determine if such factors 
play a role in the pathogenesis of the disease. 
 
It is inevitable that the occurrence of the disease in these individuals is likely to be 
multifactorial and the cases may represent a rare constellation of factors permissive 
for transmission, persistent infection and transformation to cancer. In other words, they 
may be rare occurrences that are simply stochastic events (i.e. subject to the variation 
of chance), although the odds are surely very low. It will be interesting to see if more 
couples with HPV-related OPSCC emerge as the number of incident cases of the 
disease accumulate. To date, these individuals provide evidence that the disease is 
communicable in rare circumstances, however, there is insufficient evidence to 
change the advice recommended by Fakhry and D’Souza (2013) to partners of people 
with HPV related OPSCC: 
 ‘The risk of HPV-related OPSCC may be slightly higher among spouses of 
HPV-related OPSCC, but this cancer remains rare among spouses’. 
 ‘There are no recommended screening tests for HPV-related OPSCC’. 
 ‘You have already likely shared whatever infections you have’. 
 ‘You do not need to change your sexual behavior’. 
 ‘Female partners should have regular cervical Pap screening’.[17] 
Regarding the last point, the nine females described to date were all over 50 years-
old at diagnosis and would typically be invited for cervical screening every 5 years; in 
fact, three of the patients were in their eighth decade and would not be eligible for 
screening. Consequently, there is uncertainty regarding cervical screening advice for 
women who have HPV-related OPSCC or whose partners have the disease. 
 
It is important to note that the instances of couples with HPV-related oropharyngeal 
cancer reported to date lack detailed sexual histories and may underestimate the 
burden of HPV-related disease and exposure to infection over time. Future studies 
should attempt to address these issues and also provide accurate epidemiological 
data. Such information will provide a better understanding of the risks of HPV 
transmission and can be used to counsel individuals with HPV-related SCC and their 
partners. 
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Table 1 HPV related squamous cell carcinoma in four couples. 
 
 Couple 1 Couple 2 
Sex Male Female Male Female 
Age at diagnosis 53 52 71 72 
Year of diagnosis 2010 2012 2013 2011 
Duration of 
relationship 
24 years 32 years 
Interval between 
couple diagnosis 
24 months (male index tumour) 26 months (female index tumour) 
Smoking status Former smoker 
(22 years ago) 
Never smoker Former smoker 
(28 years ago) 
Never smoker  
Alcohol Not known Not known 70 unit per week  Nil 
Site Left base of tongue Left tonsil Left base of tongue Right tonsil 
T category a T3 (T3) T2 (T2) T1 (T1) T4 (T4a) 
N category a N2 (N2c) N1 (N2b) N1 (N2b) N1 (N2b) 
M category a M0 (M0) M0 (M0) M0 (M0) M0 (M0) 
Stage a II (IVA) I (IVA) I (IVA) III (IVA) 
p16 IHC Positive Positive Positive Positive 
HR-HPV DNA ISH Positive Positive Negative Positive 
Genotype HPV16 HPV16 HPV16 HPV16 
Species European T350G European T350G European European 
Treatment Chemoradiotherapy TOLS b, left neck 
dissection, adjuvant 
radiotherapy 
Left neck dissection 
only. Declined 
further treatment 
Chemoradiotherapy 
Overall survival Alive disease free at 
85 months 
Alive disease free at 
61 months 
Alive with loco-
regional disease at 
48 months 
Dead at 9 months 
Loco-regional 
disease 
 
a UICC TNM8 (UICC TNM7). 
b TOLS = trans-oral laser surgery. 
  
Table 1 (continued) HPV related squamous cell carcinoma in four couples. 
 
 Couple 3 Couple 4 
Sex Male Female Male Female 
Age at diagnosis 64 70 61 55 
Year of diagnosis 2009 2015 2015 2014 
Duration of 
relationship 
50 years 39 years 
Interval between 
couple diagnosis 
64 months (male index) 16 months (female index) 
Smoking status Never Never Never Never 
Alcohol Nil Nil 8 units/week 4 units/week 
Site Left tonsil Right tonsil Left tongue base Right tonsil 
T category a T2 (T2) T2 (T2) T2 (T2) T2 (T2) 
N category a N1 (N2b) N1 (N2b) N1 (N2b) N1 (N2b) 
M category a M0 (M0) M0 (M0) M0 (M0) M0 (M0) 
Stage a I (IVA) I (IVA) I (IVA) I (IVA) 
p16 IHC Positive Positive Positive Positive 
HR-HPV DNA ISH Positive Positive Positive Positive 
Genotype HPV16 HPV16 HPV16 HPV16 
Species European  European  European European T350G 
Treatment Chemoradiotherapy Chemoradiotherapy Bilateral neck 
dissections, 
chemoradiotherapy 
Chemoradiotherapy 
Overall survival Alive disease free 
91 months 
Alive disease free 
32 months 
Alive disease free 
25 months 
Alive disease free 
41 months 
 
Table 2 HPV related squamous cell carcinoma previously reported in five couples [12–15] 
 
 Uemaetomari et al [12] Haddad et al [13] 
 Couple 1 Couple 1 
Sex Male Female Male Female 
Age at diagnosis 67 63 75 75 
Year of diagnosis 2004 2005 Not stated Not stated 
Duration of 
relationship 
Not stated Not stated 
Interval between 
couple diagnosis 
12 months (male index tumour) 0 months (synchronous tumours) 
Smoking status Not stated Not stated Former smoker 
(25 years ago) 
Former smoker 
(10 years ago) 
Alcohol Not stated Not stated Past heavy user 
(25 years ago) 
Non-drinker 
Site Right tonsil Left tonsil Neck 
Laterality not stated 
Right tonsil 
T category a T1 (T1) T2 (T2) TX (TX) T1 (T1) 
N category a N1 (N2b) N2 (N2c) N1 (N2a) N1 (N1) 
M category a M0 (M0) M0 (M0) M0 (M0) M0 (M0) 
Stage a I (IVA) II (IVA) I (IVA) I (III) 
p16 IHC Not stated Not stated Not stated Positive 
HR-HPV DNA ISH Not stated Not stated Not stated Not stated 
Genotype HPV16 HPV16 HPV16 HPV16 
Species Not stated Not stated European European 
Treatment Radiotherapy, 
surgery for local 
recurrence 
Radiotherapy Not stated Tonsillectomy, neck 
dissection 
Overall survival Not stated Not stated Not stated Not stated 
 
a UICC TNM8 (UICC TNM7). 
b TORS = trans-oral robotic surgery. 
  
Table 2 continued 
 
 Andrews et al [14] Brobst et al [15] 
 Couple 1 Couple 2 Couple 1 
Sex Male Female Male Female Male Female 
Age at 
diagnosis 
56 58 57 51 60 60  
Year of 
diagnosis 
Not stated Not stated Not stated Not stated Not stated Not stated 
Duration of 
relationship 
10 years 15 years 31 years 
Interval 
between 
couple 
diagnosis 
12 months (female index tumour) ‘few months’ (male index tumour) 2 months (female index tumour) 
Smoking 
status 
Former smoker 
(40 years ago) 
Never smoker Never smoker Never smoker Never smoker Current smoker 
Alcohol Non-drinker Non-drinker Non-drinker Non-drinker Occasional Occasional 
Site Right tonsil Right tonsil Right tonsil Left tonsil Left base of tongue Right tonsil 
T category a T1 (T1) T1 (T1) T2 (T2) T2 (T2) T2 (T2) T4 (T4b) 
N category a N1 (N2a) N1 (N2b) N1 (N2b) N1 (N1) N2 (N2c) N2 (N2c) 
M category a M0 (M0) M0 (M0) M0 (M0) M0 (M0) M0 (M0) M0 (M0) 
Stage a I (IVA) I (IVA) I (IVA) I (III) II (IVA) III (IVB) 
p16 IHC Positive Positive Positive Positive Positive Positive 
HR-HPV 
DNA ISH 
Not stated Not stated Not stated Not stated HR-HPV RNA ISH 
positive 
HR-HPV RNA ISH 
positive 
Genotype HPV16 HPV16 HPV16 HPV16 HPV16 HPV16 
Species European/German European/German European/German European/German Not stated Not stated 
Treatment Chemoradiotherapy 
and neck dissection 
Chemoradiotherapy 
 
Chemoradiotherapy 
 
Left neck 
dissection and 
radiotherapy 
TORS, bilateral 
neck dissection, 
chemoradiotherapy 
Chemoradiotherapy 
Overall 
survival 
Alive at 24 months Alive at 39 months Alive at 17 months Alive at 16 months Alive at 12 months Alive at 12 months 
 
